21
Participants
Start Date
September 30, 1996
Primary Completion Date
July 31, 2000
Study Completion Date
January 31, 2001
irinotecan hydrochloride
Irinotecan IV at a starting dose weekly for 4 weeks followed by 2 weeks of rest. Treatment continues in the absence of disease progression or unacceptable toxicity. Tumor status is reassessed every 12 weeks during study. Patients attaining a complete response may receive additional courses of treatment. Patients are followed until death.
Veterans Affairs Medical Center - Cleveland, Cleveland
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland
Case Comprehensive Cancer Center
OTHER